

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Vytorin (ezetimibe/simvastatin)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Vytorin (ezetimibe/simvastatin)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Vytorin (ezetimibe/simvastatin) may be approved when the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one preferred high intensity statin, or statin therapy at maximally tolerated dose, and did NOT achieve LDL cholesterol goal (AHA/ACC 2018).

Preferred high intensity statin: atorvastatin 40mg, atorvastatin 80mg.
- II. Continued therapy with Vytorin products containing simvastatin 80mg:
 - A. Individual has been on a Vytorin product containing simvastatin 80 mg for 12 months or more without evidence of muscle toxicity.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 11, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

PAGE 1 of 2 11/08/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0461-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

3. Grundy SM, Stone NJ, Bailey AL, et. al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol*. 2018. <https://doi.org/10.1016/j.jacc.2018.11.003>.
4. Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. *J Clin Lipidol*. 2014;8(3 Suppl):S72–81.
5. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. *Endocr Pract*. 2017;23(Suppl 2):1-87.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.